Fig. 6
From: DLGAP5 promotes lung adenocarcinoma growth via upregulating PLK1 and serves as a therapeutic target
The results of analysis between DLGAP5 expression and diverse drug sensitivity. A–C IC50 values of frequently-used chemotherapeutic drugs (cisplatin(A), paclitaxel (B) and docetaxel (C) in high- and low-DLGAP5 groups in LUAD (***P < 0.001). D–E) IC50 values of frequently-used molecular targeted therapeutic drugs (gefitinib (D) and erlotinib (E) in high- and low-DLGAP5 groups in EGFR-mutant (EGFR+) LUAD (*P < 0.05; **P < 0.01). F IC50 value of frequently-used molecular targeted therapeutic drug crizotinib in high- and low-DLGAP5 groups in ALK-mutant (ALK+) LUAD (**P < 0.01)